CellCarta Biosciences
The computed 12-month bankruptcy probability of CellCarta Biosciences is 0.6% (low). The 2022 annual accounts show equity of €607k and a net result of €866k. Equity is growing by ~96.6% per year across the filed fiscal years. Its solvency ranks better than 15% of 157 sector peers (fiscal year 2022). The company has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €607k |
| Net result | €866k |
| Staff (FTE) | 48.2 |
| Better than sector | 15% |
Strong profile, led by profitability.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 2.2% | 57.5% | |
| Net result | €866k | €9k | |
| Equity | €607k | €78k | |
| Gross operating margin | €6.02M | €41k | |
| Staff costs | €4.77M | €142k |
| Fiscal year | 2022 |
|---|---|
| Deposit | volledig |
| Revenue | - |
| EBITDA | €1.25M |
| Net profit | €866k |
| Cash flow | €1.23M |
| Staff costs | €4.77M |
| Income taxes | €0 |
| Dividends | - |
| Total assets | €27.69M |
| Equity | €607k |
| Debt | €27.09M |
| of which ≤ 1y | €25.29M |
| of which > 1y | €1.79M |
| Working capital | €1.30M |
| Employees (FTE) | 48.2 |
| 2022 | |
|---|---|
| Current ratio | 1.05 |
| Quick ratio | 1.05 |
| Working capital ratio | 4.7% |
| Solvency | 2.2% |
| Debt / equity | 44.60 |
| Long-term debt ratio | 2.95 |
| Interest coverage | 61.18 |
| Gross margin | - |
| Net margin | - |
| ROA | 3.1% |
| ROE | 142.6% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2022 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €27.69M |
| Fixed assets | 21/28 | €1.10M |
| Intangible fixed assets | 21 | €220k |
| Tangible fixed assets | 22/27 | €876k |
| Financial fixed assets | 28 | €162 |
| Current assets | 29/58 | €26.60M |
| Amounts receivable within one year | 40/41 | €26.11M |
| Cash & bank | 54/58 | €353k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €27.69M |
| Equity | 10/15 | €607k |
| Contributions / capital | 10/11 | €62k |
| Reserves | 13 | €6k |
| Accumulated profits (losses) | 14 | €540k |
| Amounts payable | 17/49 | €27.09M |
| Amounts payable after one year | 17 | €1.79M |
| Amounts payable within one year | 42/48 | €25.29M |
| Trade debts payable within one year | 44 | €1.89M |
| Income statement | ||
| Gross operating margin | 9900 | €6.02M |
| Operating result | 9901 | €880k |
| Financial income | 75 | €6k |
| Financial charges | 65 | €20k |
| Result before taxes | 9903 | €866k |
| Income taxes | 67/77 | €0 |
| Net result for the period | 9904 | €866k |
| Result to be appropriated | 9905 | €866k |
-
Current08-07-2025 → present
-
Current06-02-2025 → present
-
Current30-08-2023 → present
2 events
- 30-08-2023 Appointed· Director
- 30-08-2023 Appointed· Managing director
Historic, not recently confirmed (1)
-
Not recently confirmedlast confirmed in an act from 2018
Former directors (7)
-
Former13-08-2021 → 30-06-2025
3 events
- 30-06-2025 Resigned· Director
- 13-08-2021 Appointed· Director
- 13-08-2021 Appointed· Managing director
-
Former31-07-2019 → 06-02-2025
2 events
- 06-02-2025 Resigned· Director
- 31-07-2019 Appointed· Director
-
Former31-07-2019 → 30-08-2023
2 events
- 30-08-2023 Resigned· Director
- 31-07-2019 Appointed· Director
-
Former31-07-2019 → 13-08-2021
2 events
- 13-08-2021 Resigned· Director
- 31-07-2019 Appointed· Director
-
Former28-09-2018 → 31-07-2019
2 events
- 31-07-2019 Resigned· Director
- 28-09-2018 Mandate renewed· Director
-
Former28-09-2018 → 31-07-2019
2 events
- 31-07-2019 Resigned· Director
- 28-09-2018 Mandate renewed· Director
-
Former- → 31-07-2019
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| BDO BedrijfsrevisorenCurrent Statutory auditor · represented by David Lenaerts |
- | 05-01-2021 → present |
| NACE primary | Speur- en ontwikkelingswerk op biotechnologisch gebied(72101) |
| Legal form | Public limited company(014) |
| Incorporation | 18-08-2016 |
| Status | Active |
| Postal code | 6041 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 52028B0295/00F002 | Wallonia | 3,611 m² | 1 · 1,115 m² | 21.4 m · 6 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
05-02-2026 1 director appointed, 1 resigning
- Elliott Miller, Bestuurder
- Anthony Mattacchione, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Anthony Mattacchione",
"address": null,
"birth_date": null
},
"effective_date": "2025-06-30",
"evidence_quote": "Les Actionnaires prennent connaissance de la d\u00E9mission de M. Anthony Mattacchione en qualit\u00E9 d\u0027administrateur de la Soci\u00E9t\u00E9 avec effet du 30 juin 2025."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Elliott Miller",
"address": null,
"birth_date": null
},
"effective_date": "2025-07-08",
"evidence_quote": "Les Actionnaires nomment M. Elliott Miller en qualit\u00E9 de nouvel administrateur de la Soci\u00E9t\u00E9 avec effet du 8 juillet 2025."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0661.567.021",
"name_full": "CELLCARTA BIOSCIENCES",
"legal_form": "SA"
}
}11-08-2025 Roel BOONS appointed as statutory auditor
- Roel BOONS, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Roel BOONS",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0661567021",
"name": "PriceWaterhouseCoopers Bedrijfsrevisoren BV",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale nomme PriceWaterhouseCoopers Bedrijfsrevisoren BV, ayant son si\u00E8ge \u00E0 Culliganlaan 5, 1831 Diegem, repr\u00E9sent\u00E9e par monsieur Roel BOONS (B 01026) en tant que commissaire de la soci\u00E9t\u00E9 CellCarta Boisciences."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0661.567.021",
"name_full": "CELLCARTA BIOSCIENCES",
"legal_form": "SA"
}
}02-06-2025 1 director appointed, 1 resigning
- Joshua Schultz, Bestuurder
- David Spaight, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "David Spaight",
"address": null,
"birth_date": null
},
"effective_date": "2025-02-06",
"evidence_quote": "Les Actionnaires prennent connaissance de la d\u00E9mission de M. David Spaight en qualit\u00E9 d\u0027administrateur de la Soci\u00E9t\u00E9 avec effet le 6 f\u00E9vrier 2025.",
"discharge_granted": false
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Joshua Schultz",
"address": null,
"birth_date": null
},
"effective_date": "2025-02-06",
"evidence_quote": "Les Actionnaires nomment M. Joshua Schultz en qualit\u00E9 de nouvel administrateur de la Soci\u00E9t\u00E9 avec effet le 6 f\u00E9vrier 2025."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0661.567.021",
"name_full": "CELLCARTA BIOSCIENCES",
"legal_form": "SA"
}
}06-12-2024 Change in the board of directors
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0661.567.021",
"name_full": "CELLCARTA BIOSCIENCES",
"legal_form": "SA"
}
}04-12-2023 2 directors appointed, 1 resigning
- Maurice Tenney III, Bestuurder
- Maurice Tenney III, Gedelegeerd bestuurder
- Martin LeBlanc, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Martin LeBlanc",
"address": null,
"birth_date": null
},
"effective_date": "2023-08-30",
"evidence_quote": "Les Actionnaires prennent connaissance de la d\u00E9mission de M. Martin LeBlanc en qualit\u00E9 d\u0027administrateur de la Soci\u00E9t\u00E9 avec effet imm\u00E9diat\u00E9."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Maurice Tenney III",
"address": null,
"birth_date": null
},
"effective_date": "2023-08-30",
"evidence_quote": "Les Actionnaires nomment M. Maurice Tenney Iil en qualit\u00E9 de nouvel administrateur de la Soci\u00E9t\u00E9 avec effet imm\u00E9diat."
},
{
"kind": "director_in",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Maurice Tenney III",
"address": null,
"birth_date": null
},
"effective_date": "2023-08-30",
"evidence_quote": "Le Conseil d\u00E9l\u00E8gue la gestion journali\u00E8re de la Soci\u00E9t\u00E9 \u00E0 M. Maurice Tenney III avec effet imm\u00E9diat pour une dur\u00E9e ind\u00E9termin\u00E9e. M. Maurice Teriney III porte le titre d\u0027administrateur-d\u00E9l\u00E9gu\u00E9."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0661.567.021",
"name_full": "CELLCARTA BIOSCIENCES",
"legal_form": "SA"
}
}16-12-2021 2 directors appointed, 1 resigning
- Anthony Mattacchione, Bestuurder
- Anthony Mattacchione, Gedelegeerd bestuurder
- Normand Rivard, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Normand Rivard",
"address": null,
"birth_date": null
},
"effective_date": "2021-08-13",
"evidence_quote": "Les Actionnaires ont pris connaissance de la d\u00E9mission de Normand Rivard en qualit\u00E9 d\u0027administrateur de la Soci\u00E9t\u00E9 avec effet imm\u00E9diat et le remercie pour sa contribution aux affaires de la Soci\u00E9t\u00E9.",
"discharge_granted": false
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Anthony Mattacchione",
"address": null,
"birth_date": null
},
"effective_date": "2021-08-13",
"evidence_quote": "Les Actionnaires d\u00E9cident de nommer M. Anthony Mattacchione, domicil\u00E9 \u00E0 26 Harding Road, Needham, 02492 MA, Etats-Unis d\u0027Am\u00E9rique, en qualit\u00E9 de nouvel administrateur de la Soci\u00E9t\u00E9, avec effet imm\u00E9diat, pour une dur\u00E9e de six ans qui expire imm\u00E9diatement \u00E0 l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire de la Soci\u00E9t\u00E9"
},
{
"kind": "director_in",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Anthony Mattacchione",
"address": null,
"birth_date": null
},
"effective_date": "2021-08-13",
"evidence_quote": "Conform\u00E9ment \u00E0 l\u0027article 10, alin\u00E9a 2 des statuts de la Soci\u00E9t\u00E9, le Conseil d\u00E9cide de d\u00E9l\u00E9guer, avec effet imm\u00E9diat, la gestion journali\u00E8re de la Soci\u00E9t\u00E9 \u00E0 M. Anthony Mattacchione qui porte le titre d\u0027administrateur-d\u00E9l\u00E9gu\u00E9."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0661.567.021",
"name_full": "CELLCARTA BIOSCIENCES",
"legal_form": "SA"
}
}03-05-2021 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": true,
"seat_change": false,
"object_change": true,
"effective_date": "2021-05-03",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0661.567.021",
"name_full": "CAPRION BIOSCIENCES",
"legal_form": "SA"
},
"signature_regime": "joint_two",
"special_mandates": [
{
"quote": "L\u0027assembl\u00E9e conf\u00E8re tous pouvoirs \u00E0 Monsieur David Vanderstraeten, Monsieur Louis Casteleyn, Monsieur Lorenz Taets et Madame B\u00E9n\u00E9dicte Fanard, qui, \u00E0 cet effet, \u00E9lisent domicile Rue de la R\u00E9gence 4 \u00E0 1000 Bruxelles, et \u00E0 tout autre avocat ou paralegal du cabinet d\u0027avocats Jones Day, chacun pouvant agir individuellement et avec droit de substitution, afin d\u0027assurer les formalit\u00E9s aupr\u00E8s d\u0027un guichet d\u0027entreprise en vue d\u0027assurer l\u0027inscription/la modification des donn\u00E9es dans la Banque Carrefour des Entreprises et, le cas \u00E9ch\u00E9ant, aupr\u00E8s de l\u0027Administration de la Taxe sur la Valeur Ajout\u00E9e.",
"holder_kbo": null,
"holder_name": "Jones Day",
"scope_categories": [
"KBO",
"tax",
"filing"
],
"with_substitution": true
}
],
"governance_change": {
"admin_delegated_added": []
}
}05-01-2021 David Lenaerts appointed as statutory auditor
- David Lenaerts, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "David Lenaerts",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "BDO Bedrijfsrevisoren",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "L\u0027Assembl\u00E9e G\u00E9n\u00E9rale d\u00E9cide \u00E0 l\u0027unanimit\u00E9 de nommer BDO Bedrijfsrevisoren, ayant son si\u00E8ge social \u00E0 Uitbreidingstraat 72/1, 2600 Anvers, en tant que commissaire aux comptes pour une p\u00E9riode de trois ans, couvrant les exercices clos le 31 d\u00E9cembre 2020, 2021 et 2022. Le mandat prend fin apr\u00E8s l\u0027Assem"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0661.567.021",
"name_full": "CAPRION BIOSCIENCES",
"legal_form": "SA"
}
}07-01-2020 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2019-12-17",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0661.567.021",
"name_full": "CAPRION BIOSCIENCES",
"legal_form": "SA"
},
"signature_regime": null,
"special_mandates": [
{
"quote": "L\u0027assembl\u00E9e conf\u00E8re \u00E0 Ma\u00EEtre Laurence FLAMANT et/ou tout collaborateur de l\u2019\u00E9tude, \u00E0 cette fin \u00E9lisant domicile \u00E0 l\u0027adresse de la soci\u00E9t\u00E9 civile sous forme de soci\u00E9t\u00E9 coop\u00E9rative \u00E0 responsabilit\u00E9 limit\u00E9e Vanhalewyn \u0026 Flamant, 1950 Kraainem, Avenue Reine Astrid 4, tous pouvoirs afin de r\u00E9diger le texte de la coor-dination des statuts de la Soci\u00E9t\u00E9, le signer et le d\u00E9poser au greffe du tribunal de l\u2019entreprise comp\u00E9tent, conform\u00E9ment aux dispositions l\u00E9gales en la mati\u00E8re.",
"holder_kbo": null,
"holder_name": "Ma\u00EEtre Laurence FLAMANT",
"scope_categories": [
"coordination",
"publication",
"filing"
],
"with_substitution": true
}
],
"governance_change": {
"admin_delegated_added": []
}
}06-09-2019 3 directors appointed, 3 resigning
- David Spaight, Bestuurder
- Martin LeBlanc, Bestuurder
- Normand Rivard, Bestuurder
- Michael Irvin Mortimer, Bestuurder
- Andrea Ponti, Bestuurder
- Janine Nicholls, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Michael Irvin Mortimer",
"address": null,
"birth_date": null
},
"effective_date": "2019-07-31",
"evidence_quote": "Les Actionnaires ont pris connaissance et acceptent la d\u00E9mission de: \u2022 Michael Irvin Mortimer: \u2022 Andrea Ponti; et \u2022 Janine Nicholls en tant que administrateurs de la Soci\u00E9t\u00E9 avec effet imm\u00E9diat."
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Andrea Ponti",
"address": null,
"birth_date": null
},
"effective_date": "2019-07-31",
"evidence_quote": "Les Actionnaires ont pris connaissance et acceptent la d\u00E9mission de: \u2022 Michael Irvin Mortimer: \u2022 Andrea Ponti; et \u2022 Janine Nicholls en tant que administrateurs de la Soci\u00E9t\u00E9 avec effet imm\u00E9diat."
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Janine Nicholls",
"address": null,
"birth_date": null
},
"effective_date": "2019-07-31",
"evidence_quote": "Les Actionnaires ont pris connaissance et acceptent la d\u00E9mission de: \u2022 Michael Irvin Mortimer: \u2022 Andrea Ponti; et \u2022 Janine Nicholls en tant que administrateurs de la Soci\u00E9t\u00E9 avec effet imm\u00E9diat."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "David Spaight",
"address": null,
"birth_date": null
},
"effective_date": "2019-07-31",
"evidence_quote": "Les Actionnaires d\u00E9cident de nommer: \u2022 David Spaight, domicili\u00E9 \u00E0 1290 Brighton Way, Newtown Square, PA 19073, United States of America; en tant que nouveaux administrateurs de la Soci\u00E9t\u00E9, avec effet imm\u00E9diat."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Martin LeBlanc",
"address": null,
"birth_date": null
},
"effective_date": "2019-07-31",
"evidence_quote": "Les Actionnaires d\u00E9cident de nommer: \u2022 Martin LeBlanc, domicili\u00E9 \u00E0 50 Holton Avanue, Westmount, H3Y 2G2 Quebec, Canada; en tant que nouveaux administrateurs de la Soci\u00E9t\u00E9, avec effet imm\u00E9diat."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Normand Rivard",
"address": null,
"birth_date": null
},
"effective_date": "2019-07-31",
"evidence_quote": "Les Actionnaires d\u00E9cident de nommer: \u2022 Normand Rivard, domicili\u00E9 \u00E0 B51-3940 Cote des Neiges Road, Montr\u00E9al, H3H 1W2 Quebec, Canada. en tant que nouveaux administrateurs de la Soci\u00E9t\u00E9, avec effet imm\u00E9diat."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0661.567.021",
"name_full": "CAPRION BIOSCIENCES",
"legal_form": "SA"
}
}28-09-2018 3 reappointed
- MORTIMER Michael Irvine, Bestuurder
- PONTI Andrea, Bestuurder
- NICHOLLS Janine, Bestuurder
Technical details
{
"events": [
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "MORTIMER Michael Irvine",
"address": null,
"birth_date": null
},
"evidence_quote": "Prorog\u00E9 le mandat des trois administrateurs actuels, \u00E0 savoir Monsieur MORTIMER Michael Irvine, Monsieur PONTI Andrea et Madame NICHOLLS Janine, jusqu\u0027\u00E0 l\u0027issue de l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire qui sera tenue en 2024."
},
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "PONTI Andrea",
"address": null,
"birth_date": null
},
"evidence_quote": "Prorog\u00E9 le mandat des trois administrateurs actuels, \u00E0 savoir Monsieur MORTIMER Michael Irvine, Monsieur PONTI Andrea et Madame NICHOLLS Janine, jusqu\u0027\u00E0 l\u0027issue de l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire qui sera tenue en 2024."
},
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "NICHOLLS Janine",
"address": null,
"birth_date": null
},
"evidence_quote": "Prorog\u00E9 le mandat des trois administrateurs actuels, \u00E0 savoir Monsieur MORTIMER Michael Irvine, Monsieur PONTI Andrea et Madame NICHOLLS Janine, jusqu\u0027\u00E0 l\u0027issue de l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire qui sera tenue en 2024."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0661.567.021",
"name_full": "CAPRION BIOSCIENCES",
"legal_form": "SA"
}
}06-09-2016 Change in the board of directors
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0661.567.021",
"name_full": "CAPRION BIOSCIENCES",
"legal_form": "SA"
}
}22-08-2016 Incorporation of a new SNC
Technical details
{
"kind": "oprichting",
"seat": "6041 Charleroi (Gosselies), rue Adrienne Bolland 8/2",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": {
"kbo": "0660.984.526",
"name": "Caprion Biosciences Inc."
},
"kind": "rechtspersoon",
"person": null,
"share_class": "capital",
"partner_role": null,
"holder_org_kbo": "0660.984.526",
"holder_org_name": "Caprion Biosciences Inc.",
"contribution_type": "cash",
"amount_paid_in_eur": 60885.0,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 99,
"amount_subscribed_eur": 60885.0,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": "0660.984.130",
"name": "9345-8347 Qu\u00E9bec inc."
},
"kind": "rechtspersoon",
"person": null,
"share_class": "capital",
"partner_role": null,
"holder_org_kbo": "0660.984.130",
"holder_org_name": "9345-8347 Qu\u00E9bec inc.",
"contribution_type": "cash",
"amount_paid_in_eur": 615.0,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 1,
"amount_subscribed_eur": 615.0,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 61500.0,
"subject_company": {
"kbo": "0661.567.021",
"name_full": "CAPRION BIOSCIENCES",
"legal_form": "SNC"
},
"initial_directors": [],
"incorporation_date": "2016-08-18",
"post_incorporation_mandates": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | CellCarta Biosciences |